ScinoPharm Taiwan, Ltd.
1789.TW
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.1B
Close$
$8.29
56.6% downside
Current Fair Value
56.6% downsideOvervalued by 56.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.10 Billion |
|---|---|
| Enterprise Value | $12.71 Billion |
| Dividend Yield | $0.29 (1.52%) |
| Earnings per Share | $0.17 |
| Beta | 0.43 |
| Outstanding Shares | 868,655,000 |
Return
| Return on Equity | 0.36% |
|---|---|
| Return on Assets | 0.31% |
| Return on Invested Capital | -0.06% |
Valuation & Multiples
| P/E Ratio | 401.26 |
|---|---|
| PEG | -196.81 |
| Price to Sales | 6.37 |
| Price to Book Ratio | 1.59 |
| Enterprise Value to Revenue | 4.14 |
| Enterprise Value to EBIT | -1866.16 |
| Enterprise Value to Net Income | 336 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$663.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ScinoPharm Taiwan, Ltd.
1,010 employees
CEO: Li-An Lu ScinoPharm Taiwan, Ltd., along with its subsidiaries, specializes in the research, development, production, and global distribution of cGMP-compliant active pharmaceutical ingredients (APIs). The company supplies these APIs to pharmaceut...